# Myeloid/lymphoid neoplasms with eosinophilia and TK fusions

The EU has approved 2 indications of 1 drug in myeloid/lymphoid neoplasms with eosinophilia and TK fusions. Each needs a biomarker result: FIP1L1::PDGFRA (1) and PDGFR (1).

## Approved indications

### FIP1L1::PDGFRA fusion

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | FIP1L1-PDGFRalpha rearrangement | Monotherapy | Advanced | - |

### PDGFR fusion

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | PDGFR fusion | Monotherapy | Any line | - |

## Label wording

- **Imatinib** (Glivec), Myeloid/lymphoid neoplasms with eosinophilia and TK fusions, any line: “adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)
- **Imatinib** (Glivec), Myeloid/lymphoid neoplasms with eosinophilia and TK fusions, advanced: “adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/myeloid-lymphoid-neoplasms-with-eosinophilia-and-tk-fusions